entertainment -WSS

entertainment

author：hotspot 2025-10-01 17:20:14 - browse：76

A sign of pharmaceutical company Bayer in front of a blossomed tree — coverage from STAT — INA FASSBENDER/AFP via Getty Images

More hopeful news on the menopause front: Bayer announced on Monday encouraging results in two Phase 3 trials for its non-hormonal drug candidate, elinzanetant, meant to treat hot flashes. The results follow the recent market launch of Veozah, Astellas Pharma’s groundbreaking non-hormonal treatment for hot flashes, which was approved by the U.S. Food and Drug Administration last spring and received approval in the U.K., under the name Veozah, in December.

Elinzanetant is a neurokinin-1 and 3 receptor antagonist, and works by calming down the estrogen receptors in the brain that become hyperactive around menopause, causing hot flashes. The drug, a pill administered once a day, was shown to reduce both the frequency and intensity of hot flashes, and also met the secondary endpoints for improving sleep and quality of life, according to JoAnn Pinkerton, professor of obstetrics and gynecology and director of the Midlife Health at UVA Health, who is a clinical investigator for Bayer’s drug candidate.

Pinkerton said she was excited to see the broader quality of life improvements through elinzanetant: “Women have more than just hot flashes — it’s actually more about hot flushes, sweats, fatigue, lack of sleep and some of the mood changes that go on during [menopause].”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Nonprofit, backed by Microsoft, to certify AI tools in health care

explore

WSS

How to use technology to prevent future drug shortages

Q&A: Figuring out how songbirds sing may lead to better understanding of how humans learn

Male doctors called my cancer incurable. A female doctor showed it wasn't

Male doctors called my cancer incurable. A female doctor showed it wasn't

Anavex keeps shifting the goalposts in its clinical trials

Physician assistants need a new name. Here's what it should be

focus

entertainment

focus

State Dept. review finds Biden bears some blame for Afghanistan failures

The best solution to the drug shortages problem

Walensky prepares to leave CDC — and Congress — behind

Why failed clinical trials don’t always spell doom for a new drug

Novavax promises a turnaround & Lilly roils the obesity market

Methadone doses haven’t kept up in the age of fentanyl

After affirmative action ruling, medical educators look to 'holistic review'

Listen: Merck v. USA, the best of ASCO, and Leqembi at the FDA

Activists slam private health insurers over coverage restrictions

Naloxone nonprofit donates 200,000 doses after FDA approval

Wikipedia

FDA early review: GLP

For Cytokinetics, FDA rejection of heart drug would help, not hinder

At JPM 2024, hospital systems pitch financial strength to investors

What to know about Virgin Galactic's 1st mission taking paying customers to space

South Korea throws huge K

NIH trials fail to test meaningful long Covid therapies, experts say

leisure time

explore

Wikipedia

explore